Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
Returns on capital
Tenaya Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.5%
avg -46.8%
ROIC
-69.4%
avg -63.8%
ROA
-61.7%
avg -55.4%
Analysis
ROA is currently the strongest return metric at -61.7% versus its period average of -55.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Faraz Ali | President, CEO & Director | USD 983.96K | 53 | 539.78K | 0.32% |
Whittemore G. Tingley | Chief Medical Officer | USD 702.84K | 58 | — | — |
Deepak Srivastava | Scientific Founder, Chairman of Scientific Advisory Board & Director | USD 90.5K | 59 | 120.00K | 0.07% |
Eric N. Olson | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — |
Kee-Hong Kim | Chief Technology Officer | — | 60 | — | — |
Benoit G. Bruneau | Scientific Founder | — | — | — | — |
Bruce R. Conklin | Scientific Founder | — | — | — | — |
Saptarsi Haldar | Scientific Founder | — | — | — | — |
Sheng Ding | Scientific Founder | — | — | — | — |
Eric Hyllengren | CFO & Principal Accounting Officer | — | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
31
$5.04M
Net Transaction Value
−$5.04M
Net selling
Most Active
COLUMN GROUP III GP, LP
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 17, 26Aug 17, 2026 | Ali Faraz Direct | Sell | $4.1K$4,142.52 |
| Aug 17, 26Aug 17, 2026 | Ali Faraz Direct | Sell | $2.8K$2,817.20 |
| Aug 17, 26Aug 17, 2026 | Ali Faraz Direct | Sell | $3.6K$3,562.69 |
| Aug 17, 26Aug 17, 2026 | Ali Faraz Direct | Sell | $5.3K$5,256.04 |
| Aug 17, 26Aug 17, 2026 | Tingley Whittemore Direct | Sell | $1.2K$1,161.94 |
| Aug 17, 26Aug 17, 2026 | Tingley Whittemore Direct | Sell | $1.2K$1,161.94 |
| Aug 17, 26Aug 17, 2026 | Tingley Whittemore Direct | Sell | $1.3K$1,328.04 |
| Aug 17, 26Aug 17, 2026 | Tingley Whittemore Direct | Sell | $1.6K$1,617.63 |
| May 18, 26May 18, 2026 | Ali Faraz Direct | Sell | $2.7K$2,689.63 |
| May 18, 26May 18, 2026 | Tingley Whittemore Direct | Sell | $2.5K$2,476.83 |
1–10 of 31
Summary
Insiders reported 0 buys worth $0.00 and 31 sells worth $5.04M over the last 12 months. That adds up to net selling of $5.04M. COLUMN GROUP III GP, LP was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Tenaya Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TNYA's management, answered from reported figures.
Who manages TNYA?
Tenaya Therapeutics, Inc. (TNYA) lists 10 active executives. The top listed executive is Deepak Srivastava, Scientific Founder, Chairman of Scientific Advisory Board & Director.
Are TNYA insiders buying or selling?
Recent insider activity shows net buying of $221.07M.
Continue the stock analysis
Jump to another research area for this company.